References
Shimabukuro T, Nair N. Allergic Reactions Including Anaphylaxis After
Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine.JAMA . 2021 Jan 21. doi: 10.1001/jama.2021.0600. Epub ahead of
print. PMID: 33475702.
Center for Disease Control and Prevention. Allergic Reactions
Including Anaphylaxis After
Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United
States, December
14–23, 2020. https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm
Accessed
17.02.2021.
- Caballero ML, Quirce S. Excipients as potential agents of anaphylaxis
in vaccines: analyzing the formulations of the current authorized
COVID-19 vaccines. J Investig Allergol Clin Immunol. 2021 Jan 12:0.
doi: 10.18176/jiaci.0667. Epub ahead of print. PMID: 33433387.
- Sokolowska M, Eiwegger T, Ollert M, et al. EAACI statement on the
diagnosis, management and prevention of severe allergic reactions to
COVID-19 vaccines. Allergy . 2021 Jan 16. doi:
10.1111/all.14739. Epub ahead of print. PMID: 33452689.
- Worm M, Bauer A, Wedi B, et al. Practical recommendations for the
allergological risk assessment of the COVID-19 vaccination - a
harmonized statement of allergy centers in Germany. Allergol
Select. 2021 Jan 26;5:72-76. doi: 10.5414/ALX02225E. PMID: 33521511;
PMCID: PMC7841415.
- Stingeni L, Bianchi L, Tramontana M, et al. Skin tests in the
diagnosis of adverse drug reactions. G Ital Dermatol Venereol.2020;155(5):602-621.
- Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for
systemically administered drugs - an ENDA/EAACI Drug Allergy Interest
Group position paper. Allergy. 2013;68(6):702-712.
TABLE 1 Patients characteristic and adverse mucous-cutaneous reactions
in 6 patients after the first dose of Pfizer-BioNTech vaccine.